SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently the center of intense debate following the release of FDA briefing documents that challenged the efficacy and statistical analysis of its Duchenne muscular dystrophy therapy, deramiocel. Investors and the community are now focused on the upcoming advisory committee meeting, where the company will attempt to defend its trial results and address the FDAs skepticism regarding the study's statistical plan.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Investors are actively debating the sustainability of AI demand and the impact of Nvidia's $250 billion financing commitment to OpenAI, which has sparked fears of circular financing and prompted broader concerns about semiconductor sector volatility. While some community members view these heavy investments as a long-term catalyst for data center growth, others are aggressively trading the uncertainty, leading to significant price swings and heightened speculation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is facing heightened volatility and intense community debate following an arbitration ruling that dismissed the company's claims against 3D Medicines. While some investors interpret the minor financial impact and the preservation of the licensing agreement as a sign of the drug's value, others are expressing concern over the legal setback and the potential for prolonged uncertainty as the community remains hyper-focused on the long-anticipated 80th survival event and topline data from the REGAL Phase 3 trial.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is facing intense volatility as traders debate the sustainability of its rapid AI-driven growth, with sentiment swinging between optimism over expanding price targets and skepticism regarding current valuations. The community is sharply divided, balancing bullish confidence in the company's long-term data center roadmap against concerns that aggressive analyst upgrades might be serving as exit liquidity for institutional investors.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending due to reports that US officials are questioning whether an advanced EUV lithography machine may have reached China, prompting the company to strongly deny any export violations. While community discussions highlight the stock's role as a critical gatekeeper in the global semiconductor supply chain and its ongoing importance to AI infrastructure, sentiment remains mixed between long-term bullishness on its monopoly position and short-term volatility stemming from geopolitical scrutiny.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors actively discuss the stock's significant volatility alongside anticipation for next week's crucial CHMP regulatory opinion on narsoplimab. The community is focused on the impact of recent convertible debt repurchases as a potential sign of management's confidence in upcoming milestones and commercial performance.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares (SOXL) is experiencing intense volatility driven by divergent community sentiment regarding massive AI infrastructure capital expenditures and heightened geopolitical tensions in the Middle East. While some investors are actively loading the dip, betting on a semiconductor super-cycle fueled by major cloud provider spending, others are treating the price action as a bear trap and hedging with inverse ETFs as the sector grapples with broader market uncertainty.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is facing significant volatility and a sharp pullback, driven by sector-wide contagion and market sensitivity to reports of rising memory competition from Chinese entrants. Investors are actively debating whether this decline is a fundamental shift in the memory cycle or a temporary shakeout before critical upcoming earnings reports and scheduled investor updates.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as investors react to a significant expansion of its share buyback program, sparking debate over whether the move effectively signals long-term confidence in the face of broader software sector volatility. While some community members view the stock as a discounted quality play positioned for AI-driven growth, others remain cautious, pointing to regulatory concerns and high valuation multiples that demand near-perfect execution.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. (QBTS) is experiencing heightened interest as investors weigh its recent commercial expansion with AT&T alongside the stock's transition to the Nasdaq exchange. While the community is actively debating the company's long-term enterprise deal prospects versus recent macro-driven volatility in the high-beta tech sector, sentiment remains polarized between optimistic long-term holders and traders focused on short-term price swings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cancer Stocks That Are Advancing the Future of Oncology Care

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of +12.12% and +48.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -27.71% and -17.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy

Wall Street Zen raised Xilio Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.

Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8% - What's Next?

Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 4.8% - What's Next...

Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading Volume - Here's What Happened

Xilio Therapeutics (NASDAQ:XLO) Sees Strong Trading Volume - Here's Why...

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of tumor-activated immuno-oncology therapies for the treatment of cancer. The firm uses its Geographically Precise Solutions (GPS) platform to develop tumor-activated molecules, including cytokines, antibodies and other biologics. The company was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Xilio Therapeutics Inc

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

Equity

Neutral Sentiment

Above 2%

1% to 2%

Below 1%

Negative growth

The Q2 2026 GDP advance estimate lands Thursday, July 30, with the Atlanta Fed's GDPNow model nowcasting just 1.7% annualized growth, a sharp step-down from the roughly 3% pace it projected earlier in the quarter. Where do you think GDP comes in? Vote and explain your reasoning in the comments.

The Q2 GDP advance estimate releases Thursday. Atlanta Fed&#39;s GDPNow model is pointing to just 1.7% growth, down sharply from its ~3% nowcast earlier this quarter. Where do you think GDP comes in?

Stocktwits

The Q2 GDP advance estimate releases Thursday. Atlanta Fed's GDPNow model is pointing to just 1.7% growth, down sharply from its ~3% nowcast earlier this quarter. Where do you think GDP comes in?

Current Price	$8.93
Prev Close	$8.65
Open	$8.65
Dividend Yield	0.00%
50-Day Moving Average	$8.62
Beta	0.83
Avg. Volume	36,093.78
PE Ratio	-2.37

52-Week High	$12.74
52-Week Low	$6.47
Market Capitalization	$56.87M
EPS (Annual)	-$4.19
Price to Book	0.69
Revenue Per Employee	$575,868.42

Feed

News

Sentiment

Fundamentals

Info

XLOXilio Therapeutics Inc

Latest XLO News